ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2015
Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations.
Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review.Alzheimer's research & therapy · 2018Pooled it
- DNA methylation age from peripheral blood predicts progression to Alzheimer's disease, white matter disease burden, and cortical atrophy.NPJ dementia · 2025Article
- The early diagnosis of Alzheimer's disease: Blood-based panel biomarker discovery by proteomics and metabolomics.CNS neuroscience & therapeutics · 2024Review
- Clinical utility of cerebrospinal fluid biomarkers measured by LUMIPULSEAnnals of clinical and translational neurology · 2022Article
- Article
- Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques.Neurology · 2022Article
- Connected speech markers of amyloid burden in primary progressive aphasia.Cortex; a journal devoted to the study of the nervous system and behavior · 2021Article
- Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline.Alzheimer's research & therapy · 2020Article
- A Novel Deep Learning Approach with a 3D Convolutional Ladder Network for Differential Diagnosis of Idiopathic Normal Pressure Hydrocephalus and Alzheimer's Disease.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2020Article
- Disruption of cholinergic neurotransmission, within a cognitive challenge paradigm, is indicative of Aβ-related cognitive impairment in preclinical Alzheimer's disease after a 27-month delay interval.Alzheimer's research & therapy · 2020Article
- High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis.Neurology · 2019Article
- Stakeholders' Views on Early Diagnosis for Alzheimer's Disease, Clinical Trial Participation and Amyloid PET Disclosure: A Focus Group Study.Journal of bioethical inquiry · 2019Article
- Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2018Article
- Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project.JAMA neurology · 2018Article
- Review of the Ethical Issues of a Biomarker-Based Diagnoses in the Early Stage of Alzheimer's Disease.Journal of bioethical inquiry · 2018Review
- Comprehension of an Elevated Amyloid Positron Emission Tomography Biomarker Result by Cognitively Normal Older Adults.JAMA neurology · 2018Article
- Amyloid positron emission tomography candidates may focus more on benefits than risks of results disclosure.Alzheimer's & dementia (Amsterdam, Netherlands) · 2018Article
- Perspectives on Communicating Biomarker-Based Assessments of Alzheimer's Disease to Cognitively Healthy Individuals.Journal of Alzheimer's disease : JAD · 2018Article
- Patient and caregiver reactions to clinical amyloid imaging.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2017Article
- Communicating mild cognitive impairment diagnoses with and without amyloid imaging.Alzheimer's research & therapy · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Until recently, estimation of β-amyloid plaque density as a key element for identifying Alzheimer's disease (AD) pathology as the cause of cognitive impairment was only possible at autopsy. Now with amyloid-positron emission tomography (amyloid-PET) neuroimaging, this AD hallmark can be detected antemortem. Practitioners and patients need to better understand potential diagnostic benefits and limitations of amyloid-PET and the complex practical, ethical, and social implications surrounding this new technology. To complement the practical considerations, Eli Lilly and Company sponsored a Bioethics Advisory Board to discuss ethical issues that might arise from clinical use of amyloid-PET neuroimaging with patients being evaluated for causes of cognitive decline. To best address the multifaceted issues associated with amyloid-PET neuroimaging, we recommend this technology be used only by experienced imaging and treating physicians in appropriately selected patients and only in the context of a comprehensive clinical evaluation with adequate explanations before and after the scan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.